BIIB

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2002, for IDEC Pharmaceuticals Corporation (Note: The input metadata lists "BIOGEN INC.", but the filing text explicitly identifies the registrant as IDEC Pharmaceuticals Corporation). IDEC is a biotechnology company focused on targeted therapies for cancer and autoimmune diseases. Its primary revenue drivers are the copromotion of Rituxan (with Genentech) and the commercialization of ZEVALIN (approved by the FDA in February 2002).

Key Financial Metrics

Revenue Composition (9 months 2002): Revenues from unconsolidated joint business (Rituxan) accounted for $269.3 million (96% of total). Product sales (ZEVALIN) were $8.3 million. Corporate partner revenues were $3.1 million.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 49% for the three months and 47% for the nine months compared to 2001. This was driven by a 44% increase in copromotion profits from Rituxan and the introduction of ZEVALIN product sales.
• Profitability: Net income rose 43% for the quarter and 42% for the nine-month period year-over-year.
• Expense Increases: Selling, general, and administrative (SG&A) expenses surged 83% for the quarter and 82% for the nine months, primarily due to ZEVALIN commercialization costs and legal fees. R&D expenses increased 22% for the quarter and 6% for the nine months.
• Debt Issuance: In April/May 2002, the company issued $714.4 million in senior convertible notes (net proceeds $696.0 million), significantly increasing long-term debt from $136.0 million (Dec 2001) to $861.2 million (Sep 2002).
• Share Repurchase: The company used $135.0 million of the debt proceeds to repurchase common stock for treasury.

Outlook, Risks, and Management Commentary

• ZEVALIN Commercialization: While FDA approved in the U.S., European marketing approval was delayed in July 2002 due to compliance issues at a fill/finish provider. CMS assigned a fixed reimbursement rate for 2003 in November 2002.
• Rituxan Dependence: Management notes that 96% of revenues for the nine months ended Sep 30, 2002, were derived from the Rituxan copromotion arrangement. Future results are heavily dependent on Rituxan sales growth.
• Capital Projects: The company is investing heavily in new facilities, including a corporate headquarters ($177 million estimated cost) and large-scale manufacturing facilities ($400 million estimated cost). As of Sep 30, 2002, approximately $97.3 million had been invested in these projects.
• Legal Contingencies: IDEC is involved in patent litigation regarding ZEVALIN with Corixa, Coulter, and GlaxoSmithKline. An unfavorable outcome could result in injunctions or damages. Additionally, GlaxoSmithKline has sued Genentech regarding Rituxan patents; while IDEC was not named, an injunction against Rituxan would significantly harm IDEC's business.
• Product Development: In September 2002, IDEC announced it would not pursue further development of IDEC-114 for psoriasis based on Phase II results. Clinical trials for IDEC-131 were placed on a voluntary hold.

Investor Verification Checklist

• ZEVALIN Supply Chain: Verify the status of the fill/finish provider compliance issues delaying European approval and the reliability of the sole supplier for Yttrium-90 (MDS Canada).
• Rituxan Litigation: Monitor the outcome of the GlaxoSmithKline patent infringement suits against Genentech, as an injunction would eliminate IDEC's primary revenue source.
• Debt Obligations: Review the terms of the $1.2 billion face value senior notes due 2032, specifically the contingent interest provisions and put options exercisable by holders in 2005, 2007, 2012, and 2017.
• Capital Expenditure Execution: Assess the timeline and cost overruns for the new manufacturing and headquarters facilities, which are critical for future commercialization.
• Reimbursement Rates: Confirm the impact of the new CMS fixed reimbursement rate for ZEVALIN on hospital adoption and sales volume.